 |
|
|
| |
Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naïve caucasian patients with chronic HBeAg negative HBV infection
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Michel Bazinet1, Victor Pantea2, Gheorghe Placinta2, Iurie Moscalu3, Valentin Cebotarescu2, Lilia Cojuhari2, Pavlina Jimbei4, Liviu Iarovoi2, Valentina Smesnoi4, Tatiana Musteata4, Alina Jucov2, 3, Adalbert Krawczyk5, Andrew Vaillant* 1
1REPLICOR INC, Montreal, Canada, 2Department of Infectious Diseases, Nicolae Testemitanu State University of Medicine and Pharmacy , 3ARENSIA Exploratory Medicine , Republican Clinical Hospital, 4Toma Ciorba Infectious Clinical Hospital , Chisinau, Moldova, Republic of, 5Institute for Virology, Universitätsklinikum Essen, Essen, Germany
|
| |
|
|
|
|
|
